• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Certara Inc. (Amendment)

    2/13/24 5:01:03 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology
    Get the next $CERT alert in real time by email
    SC 13G/A 1 tv0575-certarainc.htm SCHEDULE 13G/A certarainc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 2)*

    Name of issuer:  Certara Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  15687V109

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  15687V109

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    59,808

    7.  SOLE DISPOSITIVE POWER

    12,370,252

    8.  SHARED DISPOSITIVE POWER

    174,308

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    12,544,560

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    7.85%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Certara Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    100 Overlook Center, Suite 101
    Princeton, NJ 08540

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    15687V109

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $CERT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CERT

    DatePrice TargetRatingAnalyst
    3/6/2026$8.00Overweight → Equal Weight
    Barclays
    2/27/2026$10.00Buy → Hold
    Craig Hallum
    1/6/2026$13.00Market Perform → Outperform
    Leerink Partners
    11/21/2025$10.00Buy
    Rothschild & Co Redburn
    11/13/2025$9.00Market Perform
    BMO Capital Markets
    9/29/2025$16.00Buy
    Craig Hallum
    7/3/2025$16.00Equal-Weight
    Morgan Stanley
    5/8/2025$14.00Equal Weight → Overweight
    Barclays
    More analyst ratings

    $CERT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Certara Inc.

    SCHEDULE 13G/A - Certara, Inc. (0001827090) (Subject)

    7/14/26 1:27:06 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Certara Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Certara, Inc. (0001827090) (Filer)

    6/17/26 4:30:24 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    SEC Form 8-K filed by Certara Inc.

    8-K - Certara, Inc. (0001827090) (Filer)

    5/15/26 4:31:48 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Certara downgraded by Barclays with a new price target

    Barclays downgraded Certara from Overweight to Equal Weight and set a new price target of $8.00

    3/6/26 8:25:25 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Certara downgraded by Craig Hallum with a new price target

    Craig Hallum downgraded Certara from Buy to Hold and set a new price target of $10.00

    2/27/26 8:32:38 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Certara upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Certara from Market Perform to Outperform and set a new price target of $13.00

    1/6/26 8:38:03 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Mohammed Faiz claimed ownership of 163,686 shares (SEC Form 3)

    3 - Certara, Inc. (0001827090) (Issuer)

    7/17/26 4:50:25 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Chief Human Resources Officer Anhalt Rona converted options into 7,147 shares and covered exercise/tax liability with 2,241 shares, increasing direct ownership by 41% to 16,789 units (SEC Form 4) (withholding tax)

    4 - Certara, Inc. (0001827090) (Issuer)

    6/2/26 5:15:27 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    SVP and General Counsel Corcoran Daniel converted options into 22,830 shares and covered exercise/tax liability with 12,103 shares, increasing direct ownership by 50% to 32,046 units (SEC Form 4) (for tax liability)

    4 - Certara, Inc. (0001827090) (Issuer)

    6/2/26 5:14:47 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026

    RADNOR, Pa., July 15, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2026 before market open on Tuesday, August 4th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara transforms drug discovery and devel

    7/15/26 4:15:00 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Certara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent Toolkit

    RADNOR, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, is partnering with NVIDIA to advance Certara's open integrated AI platform, unifying its scientific software, regulatory expertise, and proprietary datasets with AI-first, agentic frameworks. The NVIDIA BioNeMo Agent Toolkit turns any AI agent into an autonomous life sciences scientist, providing access to NVIDIA’s full life science stack. Within Certara's platform, BioNeMo Agent Toolkit serves as one of several agentic frameworks available to clients, working alongside Certara's biosimulation models, regulatory expertise, and scientific teams to accelerate insig

    7/7/26 8:00:00 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel

    A wave of government funding, hardware progress, and looming encryption deadlines has turned quantum from a lab curiosity into one of the most closely watched corners of the market in 2026, spanning computing hardware and the cybersecurity built to survive it.VANCOUVER, BC, July 6, 2026 /CNW/ -- USA News Group News Commentary, For years, quantum computing lived mostly in research papers and conference keynotes. In 2026 it has become something harder to ignore: a sector with federal capital behind it, a string of technical milestones on the board, and a parallel race to rebuild the world's encryption before quantum machines can break it. The result is one of the most polarizing themes in the

    7/6/26 8:45:00 AM ET
    $ABSI
    $AZN
    $CERT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Computer Software: Prepackaged Software

    $CERT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Feehery William F bought $200,000 worth of shares (24,096 units at $8.30), increasing direct ownership by 1% to 2,360,769 units (SEC Form 4)

    4 - Certara, Inc. (0001827090) (Issuer)

    11/12/25 4:44:55 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    Leadership Updates

    Live Leadership Updates

    View All

    The Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath It

    Issued on behalf of MindWalk Holdings Corp.Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.NEW YORK, June 16, 2026 /CNW/ -- Equity Insider News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, models that can predict how a protein folds or design an antibody from scratch. But a quieter and increasingly influential argument is taking hold among the people actually

    6/16/26 8:45:00 AM ET
    $ABSI
    $CERT
    $HYFT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Computer Software: Prepackaged Software
    Technology

    Certara Appoints Jon Resnick as Chief Executive Officer

    Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial growth William Feehery to step down as CEO on December 31, 2025 Company reaffirms full year 2025 financial outlook RADNOR, Pa., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, announced today that it has appointed Jon Resnick as its next Chief Executive Officer and member of Certara's Board of Directors, effective January 1, 2026, succeeding William F. Feehery, who will at that point serve as an external advisor during a transition period. Resnick brings over 20 years of experience with IQVIA, a g

    12/11/25 6:00:00 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform

    RADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief Technology Officer. In this role, Bouton will lead technology strategy and development of a next-generation integrated model-informed drug development (MIDD) platform, which is enabled by generative AI and advances in biosimulation technology. Dr. Bouton was the founder and CEO of Vyasa Analytics, acquired by Certara in 2022. Vyasa provided scalable deep-learning software, which allows Certara software to make new predictions and answer complex questions across structured and unstructured data

    7/31/25 4:15:00 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    Financials

    Live finance-specific insights

    View All

    Certara to Report Second Quarter 2026 Financial Results on August 4th, 2026

    RADNOR, Pa., July 15, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2026 before market open on Tuesday, August 4th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara transforms drug discovery and devel

    7/15/26 4:15:00 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Certara Reports First Quarter 2026 Financial Results

    RADNOR, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its first quarter 2026 financial results. First Quarter Highlights: Revenue was $106.9 million, compared to $106.0 million in the first quarter of 2025, representing growth of 1%. Software revenue was $49.7 million, compared to $46.4 million in the first quarter of 2025, representing growth of 7%.Services revenue was $57.2 million, compared to $59.6 million in the first quarter of 2025, representing a decrease of 4%. Net loss was $8.8 million, compared to a net income of $4.7 million in the first quarter of 2025, representing a decrease of 285%.A

    5/11/26 6:25:00 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Certara to Report First Quarter 2026 Financial Results on May 11th, 2026

    RADNOR, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it will release financial results for the first quarter of 2026 before market open on Monday, May 11th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Certara website at https://ir.certara.com/. About CertaraCertara accelerates medicines using biosimulat

    4/9/26 4:15:00 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    $CERT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Certara Inc.

    SC 13G - Certara, Inc. (0001827090) (Subject)

    11/14/24 8:38:56 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by Certara Inc.

    SC 13G/A - Certara, Inc. (0001827090) (Subject)

    10/4/24 10:25:50 AM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G/A filed by Certara Inc. (Amendment)

    SC 13G/A - Certara, Inc. (0001827090) (Subject)

    2/13/24 5:01:03 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology